Fairvalue-Calculator Fairvalue-Calculator
EN DE

Raia Drogasil S.A (RADL3) Fair Value & Analysis

Healthcare · BR · Market cap R$30.5B

PriceR$17.00
Fair ValueR$15.58
Upside-8.4%
Quality95/100
Evidence: High Range R$10.81 – R$23.14

Fair value as of: Jun 24, 2026

Analysis

Raia Drogasil S.A (RADL3) currently trades at R$17.00, while our model-based Fair Value estimate is R$15.58 — implying the stock looks roughly 8.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Raia Drogasil S.A. engages in the retail sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics and specialty medicines in Brazil. The company sells its products through stores, telesales, and call centers. Raia Drogasil S.A. was founded in 1905 and is headquartered in São Paulo, Brazil.

Open the full interactive analysis →

Similar stocks

JD Health International Inc (JDHIF) +376% Alibaba Health Information Technology Limited (ALBBY) -20% Yifeng Pharmacy Chain Co (603939) +106% Clicks Group (CLCGY) +45% Sugi Holdings (SGIPF) +83% Corporativo Fragua, S.A. (CGSBF) -1%

Frequently asked questions

Is Raia Drogasil S.A (RADL3) undervalued?
As of Jun 24, 2026, our model estimates a fair value of R$15.58 versus a price of R$17.00 — about −8% (overvalued). Model-based estimate, not financial advice.
What is the fair value of RADL3?
Our 21-model fair value for Raia Drogasil S.A is R$15.58 (as of Jun 24, 2026), built from audited fundamentals. The current price is R$17.00.
What is the quality score of RADL3?
Raia Drogasil S.A has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.